{"id":"NCT01855750","sponsor":"Janssen Research & Development, LLC","briefTitle":"A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma","officialTitle":"A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-09-03","primaryCompletion":"2018-02-26","completion":"2019-04-05","firstPosted":"2013-05-16","resultsPosted":"2019-03-19","lastUpdate":"2025-02-04"},"enrollment":838,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Lymphoma"],"interventions":[{"type":"DRUG","name":"Ibrutinib","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Rituximab","otherNames":[]},{"type":"DRUG","name":"Cyclophosphamide","otherNames":[]},{"type":"DRUG","name":"Doxorubicin","otherNames":[]},{"type":"DRUG","name":"Vincristine","otherNames":[]},{"type":"DRUG","name":"Prednisone (or equivalent)","otherNames":[]}],"arms":[{"label":"Treatment Arm A: placebo + R-CHOP","type":"PLACEBO_COMPARATOR"},{"label":"Treatment Arm B: ibrutinib + R-CHOP","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate if ibrutinib administered in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) improves the clinical outcome in newly diagnosed patients with non-germinal center B-cell subtype (GCB) of diffuse large B-cell lymphoma (DLBCL) selected by immunohistochemistry (IHC) or newly diagnosed patients with activated B cell-like (ABC) subtype of DLBCL identified by gene expression profiling (GEP) or both populations.","primaryOutcome":{"measure":"Event-Free Survival (EFS) - Intent-to-Treat (ITT) Population","timeFrame":"Up to 5.5 years","effectByArm":[{"arm":"Treatment Arm B: Ibrutinib+R-CHOP","deltaMin":49.64,"sd":null},{"arm":"Treatment Arm A: Placebo+R-CHOP","deltaMin":54.77,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.5167"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":12},"locations":{"siteCount":201,"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","China","Czechia","Denmark","Finland","France","Germany","Hungary","Israel","Japan","Mexico","Netherlands","Norway","Poland","Russia","South Korea","Spain","Sweden","Taiwan","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["39563886","36696540","34739844","30901302"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":221,"n":416},"commonTop":["Neutropenia","Nausea","Anaemia","Fatigue","Diarrhoea"]}}